Digital Medicine Society (DiMe)’s Post

Today, I had the honour of chairing a panel discussion at the conference we organised on health-related needs as drivers for healthcare policy and innovation.  During the panel discussion, the experts delved into ways of guiding pharmaceutical innovation in order to meet the needs of patients and society within our European healthcare system more effectively. They also discussed the financial landscape of pharmaceutical research and development, identifying obstacles and suggesting tactics to adopt a more needs-driven approach. This conference marks another crucial step ahead as we keep working together on this very important topic.

https://lnkd.in/dqVGarwG Today, on International Clinical Trials day, it's important to think about how we can ensure that the European Clinical Trials Ecosystem can evolve to better embrace new technologies, become more patient centred and better meet the the needs of patients, health care systems and clinical trials investigators. Please read this blog authored together with Stefan Schwoch, Max Wegner and the staff at EFPIA - European Federation of Pharmaceutical Industries and Associations.

We are delighted to share with you our new paper “Maximizing the Value of Real‐World Data and Real‐World Evidence to Accelerate Healthcare Transformation in China: Summary of External Advisory Committee Meetings” just published in Pharmaceutical Medicine Journal! Thank you to everyone involved for helping to make this achievement happen. To discover how RWD sources are empowering clinical practice and patient management in China, you can read the manuscript here: https://lnkd.in/eWVFksct

⏱️ Only 11 months (-1 day) left before EU HTA becomes reality! It is critical that all stakeholders work together to make the implementation a success for patients in Europe. Especially in times where not all is clear yet... 💬 At World Evidence, Pricing and Access Congress we will hold a panel discussion on "EU HTA: How to ensure stakeholder alignment on a national level to accelerate broad patient access?" 👉 Please join Neil Grubert, Mihai Iulian Rotaru (EFPIA - European Federation of Pharmaceutical Industries and Associations), Herbert Altmann (Cencora PharmaLex) and myself (Vintura) in this discussion! 📍 12 March, 12:45 CET Hope to see you there, or at any other moment during the conference. Cencora, Cencora | Pharma solutions

An excellent paper Carmen Moreno Redondo! Once again real-world data (RWD) is continuing to show promise in improving evidence generation and patient outcomes globally. This paper highlights what we continue to do at Cisiv Ltd, accelerating healthcare transformation by taking a patient-centric approach, which is essential for unlocking RWD's full potential. Add this to your reading list! #realworldevidence #realworlddata #patientoutcomes

Free webinar on the Nordic pharmaceutical market and key trends hosted by our partners in Finland, Pharmaca. You are welcome to join! Pharmaca Health Intelligence

CQDM. We celebrate. 15th anniversary of CQDM. 2018: Creation of CATALIS After starting the initiative and hosting the CATALIS structure, the CQDM, in 2018, created the neutral and independent entity CATALIS Québec which holds the government mandate to optimize the clinical research environment in Quebec in collaboration with the various life sciences players to accelerate the development of innovative treatments for the benefit of patients. Since its creation, CATALIS has continued to expand its Network, which today has nearly 70 public-private partners, including 23 establishments in the health and social services network, as well as 15 pharmaceutical companies. Among CATALIS' major achievements is the FAST TRACK Evaluation Service, which aims to authorize clinical trials in 8 weeks, a reduction of almost 75% of the global standard authorization time. This Service has already enabled several health establishments in Quebec to be the first activated sites in the world, thus positioning Quebec on the global stage of clinical research. “I would like to thank Diane Gosselin, CEO of CQDM, for her commitment and great contribution to the CATALIS mission, as well as for her role as executive president of the CATALIS board of directors from 2017 to 2020. I am proud to note the path traveled by CATALIS thanks to the strength of our collaborations. I will continue to leverage the know-how of our entire team and mobilize our large network of partners, to ensure the success of our mission and the growth of our organization. » declared Danika Laberge, CEO of CATALIS Québec. More info: https://lnkd.in/esdAJAgt.. #lifesciences #biotechnology #drugdevelopment #innovation #funding #projects #medical #research #intelligenceartificielle #artificialintelligence #pharmaceutique #pharmaceutical #biopharma #biopharmaceutical #rna #rnatherapeutics #arn #faciliterinnovationbiopharma #anniversaire #anniversary

Congratulations Michael Boyd! You'll be great in this, and I couldn't agree with you more. On that note, here's the link to a nice ebook (just published by the incredible Jill Donahue, Fueling the power of purpose in pharma teams), which tells the stories of 100 pharma leaders, a tool perhaps to leverage in telling a piece of our story: A Dose of Inspiration: 100 Purpose Stories from Pharma Leaders (https://lnkd.in/efCEvCX8)

We recently hosted a session at Nordic Life Science Days 2024, where industry leaders gathered to discuss the challenges and opportunities in advancing patient centricity within the pharmaceutical sector.   Despite the ongoing efforts across the industry to address patient needs throughout drug discovery, development, and commercialization, significant gaps remain. These challenges include identifying unmet needs early on, navigating increasingly complex clinical trials, and ensuring product availability.   Dr. Ulrica Sehlstedt, Arthur D. Little’s Global Leader for the Healthcare & Life Sciences practice, moderated a panel featuring Christophe Bourdon, CEO of LEO Pharma; Kati Kaijasilta, Business Development Director at Orion Pharma Ltd; Mike Ryan, General Manager Europe at EVERSANA; and Dr. Holger Kissel, Senior Vice President Scientific Relations and Liaison at BioNTech SE. Together, they explored how leading pharmaceutical companies are working to overcome these challenges to enhance patient value and achieve commercial success.   The discussions were insightful, and while we are encouraged by the innovative progress being made, it is clear there is still much work ahead. We look forward to continuing to collaborate across the industry to drive further improvements for patients.   #NLSDays #HealthcareInnovation #PatientCentricity